Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Alan S. Coates, Andrew Tutt, Binghe Xu et al.|Annals of Oncology|2015Cited by 1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyGeorge W. Sledge, Antonio Llombart‐Cussac, Masakazu Toi et al.|Journal of Clinical Oncology|2017Cited by 1.7k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017Giuseppe Curigliano, Andrew Tutt, Harold J. Burstein et al.|Annals of Oncology|2017Cited by 1.3k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2George W. Sledge, Antonio Llombart‐Cussac, Masakazu Toi et al.|JAMA Oncology|2019Cited by 983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upSibylle Loibl, Nadia Harbeck, Fabrice André et al.|Annals of Oncology|2023Cited by 830